Affimed NV (STU:A28A)
€ 1.1 -0.045 (-3.93%) Market Cap: 18.70 Mil Enterprise Value: 6.65 Mil PE Ratio: 0 PB Ratio: 1.07 GF Score: 30/100

Affimed NV Corporate Call Transcript

Apr 14, 2021 / 08:05PM GMT
Release Date Price: €84.8 (+0.95%)
Operator

Good day, everyone, and welcome to Affimed's conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to introduce your host for today's conference call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, John. I'd like to welcome everyone, and thank you for joining us today to discuss clinical data presented by MD Anderson at AACR on the combination therapy of AFM13, pre-complexed cord blood-derived natural killer cells with AFM13, followed by 3 weekly infusions of AFM13 monotherapy.

I would also like to apologize for the late start to the call. We were experiencing technical difficulties.

On the call today, we have our CEO, Dr. Adi Hoess, and a special guest for today is Dr. Katy Rezvani, Professor of Stem Cell Transplantation and Cellular Therapy at the University of Texas MD Anderson Cancer Center. In addition to Adi and Dr. Rezvani, we have the rest of our management team: Dr. Andreas

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot